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Background: Inhaled indacaterol (Onbrez Breezhaler), a long-acting β2-agonist, is approved in over 100 countries, 
including South Korea, as a once-daily bronchodilator for maintenance and treatment of chronic obstructive pulmonary 
disease (COPD). Here, we present an interim analysis of a post-marketing surveillance study conducted to evaluate the 
real-world safety and effectiveness of indacaterol in the Korean population.
Methods: This was an open-label, observational, prospective study in which COPD patients, who were newly prescribed 
with indacaterol (150 or 300 μg), were evaluated for 12 or 24 weeks. Safety was assessed based on the incidence rates of 
adverse events (AEs) and serious adverse events (SAEs). Effectiveness was evaluated based on physician’s assessment by 
considering changes in symptoms and lung function, if the values of forced expiratory volume in 1 second were available.
Results: Safety data were analyzed in 1,016 patients of the 1,043 enrolled COPD patients receiving indacaterol, and 
784 patients were included for the effectiveness analysis. AEs were reported in 228 (22.44%) patients, while 98 (9.65%) 
patients reported SAEs. The COPD condition improved in 348 patients (44.4%), while the condition was maintained in 
396 patients (50.5%), and only 40 patients (5.1%) exhibited worsening of ailment as compared with baseline. During the 
treatment period, 90 patients were hospitalized while nine patients died. All deaths were assessed to be not related to the 
study drug by the investigator.
Conclusion: In real-life clinical practice in South Korea, indacaterol was well tolerated in COPD patients, and can be 
regarded as an effective option for their maintenance treatment.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive lung disease characterized by persistent airflow 
limitation which is associated with an enhanced chronic 
inflammatory response to noxious particles or gases1. Ac-
cording to the Global Burden of Disease Study reports, COPD 
is projected to become the third leading cause of mortality 
worldwide by 20201. In South Korea, the prevalence of COPD 
has been reported as 12.2%–15.5% in 2012, as per the 5th 
Korean National Health and Nutrition Examination Survey 
(KNHNES)2. Bronchodilators remain the cornerstone of 
pharmacological management of COPD patients. The current 
Global Initiative for Chronic Obstructive lung Disease (GOLD) 
guidelines recommend inhaled long-acting bronchodila-
tors such as long-acting β2-agonists (LABAs) and long-acting 
muscarinic antagonists (LAMAs) for management of patients 
with moderate-to-severe COPD1. Once-daily indacaterol is 
the first approved LABA, inhaled using the Breezhaler device 
(Onbrez Breezhaler; Novartis, Basel, Switzerland) for main-
tenance bronchodilator treatment of COPD patients3. It was 
first approved in the European Union in 2009 as a once-daily 
treatment at doses of 150 and 300 μg4; since then, it has been 
approved in over 100 countries worldwide for the mainte-
nance treatment of COPD5. Indacaterol received approval for 
maintenance bronchodilator treatment of COPD patients in 
South Korea in 2010. 
In clinical studies, once-daily indacaterol showed statistical-
ly significant and clinically meaningful improvements in lung 
function, improved dyspnoea, reduced rescue medication use 
and improved quality of life (QoL) in patients with moderate-
to-severe COPD4,6. In a 12-week study conducted in Asian pa-
tients with moderate-to-severe COPD, including patients from 
Korea, indacaterol (150 and 300 μg) showed effective bron-
chodilation and improvements in patient-reported outcomes. 
Moreover, indacaterol had a good safety profile and tolerabil-
ity in this population7. Furthermore, in a 12-week post-hoc 
analysis conducted in an Asian COPD population, indacaterol 
treatment demonstrated clinically important improvements 
in lung function, dyspnoea, and health status8.
This post-marketing surveillance (PMS) was conducted to 
meet the local Health Authority regulatory requirements in 
South Korea, in order to identify unexpected adverse events 
(AE), if any, and their frequency as well as to understand the 
factors that may influence the safety and effectiveness of in-
dacaterol in COPD patients. The report presented here is an 




This was an open-label, observational, prospective study 
in which the eligible patients were newly treated with inda-
caterol (150 or 300 μg) in its approved indication according to 
the routine medical practice, over a 12- or 24-week treatment 
period, as applicable. In this PMS study; recruitment of more 
than 3,000 patients is planned until 2016 according to the 
Korean Health Authority regulatory guidelines. The study was 
designed and conducted in accordance with the guidelines 
for Good Pharmaco-epidemiology Practices and is in compli-
ance with the ethical principles stated in the Declaration of 
Helsinki. The study protocol was approved by the institutional 
review board of each study center.
2. Study population
The inclusion criteria of subjects were physician-diagnosed 
COPD patients aged 18 and over, prescribed with indacaterol 
either 150 or 300 μg for the maintenance treatment. The 
exclusion criteria were patients with hypersensitivity to inda-
caterol capsule or any of the ingredients of the capsule, or with 
lactose intolerance, or with asthma. The written informed 
consent of patients for participation in this study was directly 
taken by each investigator. Patients with hypersensitivity to 
indacaterol capsule or any of the ingredients of the capsule, or 
with lactose intolerance, or with asthma, were not included in 
the study. 
3. Assessments 
Safety evaluation was based on the incidence of AEs and 
serious adverse events (SAEs) during routine drug use. An 
AE was defined as any unfavourable and unintended sign (in-
cluding an abnormal laboratory finding), symptom or disease 
(new disease or worsening of existing disease) occurring after 
the start of the study medication. Data were collected and 
recorded, whether volunteered by the subject, discovered by 
investigator questioning or detected through physical exami-
nation, laboratory test or by any other means. Any event was 
regarded as an SAE, if any one of the following occurred: (1) 
AE resulting in death/life-threatening condition, (2) required 
hospitalisation or prolongation of hospitalization, (3) resulted 
in persistent or significant disability/inability, (4) resulted in a 
congenital anomaly or a birth defect, and (5) important medi-
cal event that jeopardized the subject or may require medical 
or surgical intervention to prevent one of the outcomes listed 
above. 
Classification of AEs for this study was based on the Medical 
Dictionary for Regulatory Activities (MedDRA) 16.0 Classifi-
cation Criteria. Incidences of AEs and SAEs, unexpected AEs 
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and SAEs which were defined as events not listed in the local 
label were also assessed. During recording of AEs, following 
information was included type of AE; onset and stop date; 
severity (mild, moderate, or severe); any SAE occurrence; 
outcome of AEs; relationship to the study drug; or any con-
comitant medications, disease, action taken, and treatment 
given. The severity of AEs was determined as follows: mild, 
symptom(s) not interfering with the patient’s daily activities 
and continuous treatment with same dose of indacaterol is 
possible; moderate, symptom(s) were interfering with the pa-
tient’s daily activities so that the dose decrease of indacaterol 
or any treatment is needed; and severe, symptom(s) resulting 
in the patient’s inability to undertake daily activities or dis-
continuation of indacaterol due to AEs. Several factors were 
considered to check whether there was any relationship with 
the safety variables. These factors were gender, age, disease 
duration, history of COPD exacerbation, smoking history, 
treatment duration, average daily dose of indacaterol, comor-
bidities, and concomitant drugs or concomitant therapies 
used.
Effectiveness was evaluated by interviewing the patients 
by trained and certified physicians and also based on change 
from baseline in forced expiratory volume in 1 second (FEV1) 
when the pulmonary function test results were available at 
site. Change in COPD condition at week 12 or 24 (whichever 
applicable) was assessed in terms of ‘improved’ (improvement 
of symptoms) or ‘maintained’ (little change shown from base-
line) or ‘worsening’ (symptoms worsened from baseline) or 
‘not assessable’ (assessment is not possible because of loss to 
follow-up or other reasons). Since indacaterol was approved 
as a maintenance treatment for COPD patients, both ‘im-
proved’ and ‘maintained’ were assessed as being ‘effective.’ 
4. Statistical analysis
For AEs, the number of the subjects and the number of 
cases of AEs were calculated. The incidence rates and their 
95% confidence intervals (CIs) were estimated and analyzed 
using the chi-square test or Fisher exact test. The number of 
cases and the percentage of AEs were calculated according to 
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Figure 1. Selection of study patients 
(patient disposition). CRF: case report 
forms.
Table 1. Patient demographics and baseline characteristics
Variable No. (%)
Age, yr
    Mean±SD 69.1±9.2
    ≥65 731 (72)
Gender
    Male 891 (87.7)
Treatment type*
    Outpatient 984 (97.2)
    Hospitalization 28 (2.8)
Duration of COPD, mo
    Mean±SD 32.9±47.3
History of COPD exacerbation
    Yes 244 (24.0)
    No 772 (76.0)
Smoking history†
    Non-smoker 188 (18.8)
    Current smoker 211 (21.1)
    Ex-smoker 603 (60.2)
Medication for COPD treatment
    LABA/ICS 133 (13.1)
    LAMA 363 (35.7)
    ICS use 148 (14.6)
    Theophylline 29 (2.9)
    Rescue medication 64 (6.3)
Baseline FEV1, L
    Mean±SD 1.46±0.5
*Data for four patients were not recorded. †Data for 14 patients 
were not recorded. 
SD: standard deviation; COPD: chronic obstructive pulmonary 
disease; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; 
LAMA: long-acting muscarinic antagonist; FEV1: forced expiratory 
volume in 1 second.
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taken with regard to the study drug, and treatment for AEs. 
AEs/SAEs whose causality was related to the study drug were 
referred to as ‘adverse drug reactions.’ Patients excluded from 
the safety analysis set were those who ‘did not take the study 
drug’ and those ‘who was lost to follow-up.’ 
FEV1 values at week 12 or 24 (as applicable) from baseline 
(before administration) were recorded (if the patients under-
went a spirometry test) and the changes before and after study 
drug administration were analyzed using the paired t test. The 
effectiveness rate was assessed according to demographic 
data including key factors such as age, gender, duration of dis-
ease, exacerbation history, smoking history, total duration of 
treatment, total dosage, treatment discontinuation and its rea-
son, concomitant medication use and its type, concomitant 
treatment and its type. The effectiveness rate and its 95% CIs 
were then estimated and analyzed using the chi-square test or 
Fisher exact test. Multivariate logistic regression analysis was 
performed to find factors affecting effectiveness rate and inci-
dence rate of AEs. All statistical analysis was performed using 
SAS release version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
1. Patient disposition 
Of the 1,043 enrolled patients, 1,016 patients (97.4%) were 
included in the safety analysis set. Of these, 784 patients 
(77.2%) were part of the effectiveness analysis set while 232 
patients (22.8%) were excluded due to inability to assess their 
final effectiveness (i.e., those who did not visit at week 12 and 
week 24) (Figure 1).
2. Patient demographics and baseline characteristics
Patient demographics and baseline characteristics are 
presented in Table 1. The average patient age was 69.1±9.2 
years and 87.7% of patients were male. Most patients were fol-
lowed up at outpatient clinic (97.2%) and 76% of patients had 
no history of exacerbation in the previous 12 months. Prior 
to study enrolment, 13.1% and 35.7% of patients were using 
inhaled corticosteroids (ICS)/LABA and LAMA, respectively. 
ICS use including ICS/LABA at baseline was 14.6% of patients. 
Spirometry was available for 476 patients with the mean FEV1 
as 1.46±0.47 L. On an average, patients were treated with 
indacaterol for 150.3±66.1 days. Majority of patients (91.2%) 
received the daily treatment dose of 150 μg while only 7.6% of 
the patients received 300 μg. 
Table 2. AEs and SAEs (safety set)
Incidence rate, n (%) 95% CI
Any AEs 228 (22.44) 19.91–25.13
    Most frequent AEs by preferred term
        Cough 41 (4.04) 2.91–5.43
        Dyspnoea 30 (2.95) 2.00–4.19
        COPD worsening 18 (1.77) 1.05–2.79
        Pneumonia 18 (1.77) 1.05–2.79
    Adverse drug reactions* 50 (4.92) 3.67–6.44
    Most frequent adverse drug reactions
        Cough 28 (2.76) 1.84–3.96
        Drug ineffective 9 (0.89) 0.41–1.67
        Dyspnoea 4 (0.39) 0.11–1.00
Any SAEs 98 (9.65) 7.9–11.63
    Most frequent SAEs by preferred term
        Dyspnoea 19 (1.87) 1.13–2.91
        Pneumonia 17 (1.67) 0.98–2.67
        COPD 14 (1.38) 0.76–2.30
    Adverse drug reactions* 1 (0.10) 0.00–0.55
*Defined as AEs/SAEs whose causality was related to the study drug. 
AEs: adverse events; SAEs: serious adverse events; CI: confidence intervals; COPD: chronic obstructive pulmonary disease.
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3. Safety assessments
Overall, 228 patients (22.44%) reported at least one AE with 
a total of 313 cases of AEs, during this interim analysis. The 
most common AEs were cough (4.04%) followed by dyspnoea 
(2.95%), COPD worsening (1.77%), and pneumonia (1.77%). 
‘Adverse drug reactions’ occurred in 50 patients (4.92%). 
Cough (2.76%), drug ineffective (0.89%), and dyspnoea 
(0.39%) were the most frequent adverse drug reactions in 
these patients (Table 2).
SAEs were reported by 98 patients (9.65%) with a total of 
131 cases during this interim analysis. Of 1,016 patients the 
most frequent SAEs were dyspnoea (1.87%, 19) followed by 
pneumonia (1.67%, 17), and COPD worsening (1.38%, 14) 
(Table 2). 
Some of the cases of the reported AEs and SAEs were 
unexpected, which are defined in the protocol as the events 
not listed on the local label of the study drug; 13% of patients 
reported 169 AEs while 8.2% of patients reported 105 SAEs 
without expectation. SAE suspected to be related to the study 
medication was orthostatic hypotension, which was reported 
by one patient. Ninety patients in this study population were 
hospitalized and nine patients died during the treatment pe-
riod. All death was assessed to be not related to study medica-
tion as determined by the investigator.
Among 313 reported AEs, majority of them were ‘mild’ 
(61.3%) while the proportion of ‘moderate’ and ‘severe’ cases 
was lower (27.8% and 10.9%, respectively) (Figure 2). The AEs 
could either be resolved completely (67.1%), or on recovery 
(20.1%) while some of them were not resolved (10.5%), re-
solved with sequela (0.7%) or remained worsened (1.6%). For 
the management of AEs, the most common action taken with 
the study drug was no change (77.6%) followed by perma-
nently discontinued (20.8%), temporarily discontinued (1.3%), 
and dosage increased (0.3%).
There were no differences in the incidence rate of AEs either 
by gender or age. However, a statistically significant difference 
in the incidence rate was observed for patients who suffered 
from COPD for more than 3 years as compared with patients 
who had the disease for less than 1 year (28.41% vs. 19.76%, 
respectively; p=0.045). In addition, an analysis of the incidence 
of AEs based on the presence and absence of COPD exac-
erbations revealed that 35.25% (86/244) of the patients with 
AEs had experienced a COPD exacerbation, while 18.39% 
(142/772) had not (p<0.001) (Table 3). Multivariable analysis 
showed that COPD exacerbation history (relative ratio [RR], 
1.88; p=0.001), previous medical history (RR, 2.05; p<0.001), 


















Figure 2. Severity of AE (safety set). *For 313 AEs reported by 228 
patients. AEs: adverse events.
Table 3. Factors associated with incidence rate of AEs: 
univariate analysis
Variable Incidence rate, n (%) p-value 
Duration of COPD, mo
    <12 82 (19.76) 0.045 
    ≥12 and <24 16 (19.05)
    ≥24 and <36 21 (25.93)
    ≥36 77 (28.41)
Age, yr
    <60 31 (21.09) 0.558
    60–70 70 (20.90)  
    ≥70 127 (23.78)
Gender  
    Male 205 (23.01) 0.248
    Female 23 (18.40)
History of exacerbation
    Yes 86 (35.25) <0.001
    No 142 (18.39)
Comorbidities
    Yes 203 (25.50) <0.001
    No 25 (11.36)
Previous medical history
    Yes 141 (28.89) <0.001
    No 87 (16.48)
Concomitant drugs
    Yes 222 (24.16) <0.001
    No 6 (6.19)
Concomitant therapies
    Yes 10 (76.92) <0.001
    No 218 (21.73)
p-value by chi-square test.
AE: adverse event; COPD: chronic obstructive pulmonary disease.
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3.45; p=0.01), and concomitant therapies used (RR, 7.91; 
p=0.003) were the factors that affects the incidence rate of AEs 
(Table 4).
4. Effectiveness assessments
Physicians subjectively assessed the patient’s overall status 
based on the changes in FEV1 and symptom improvement at 
week 12 or 24, through proportions of ‘improved’, ‘maintained’ 
Table 4. Multivariate logistic regression analysis of factors 
associated with incidence rate of AEs and effectiveness rate
Variable OR 95% CI p-value
Incidence rate of AEs
    COPD exacerbation history 1.88 1.28–2.77 0.001
    Previous medical history 2.05 1.45–2.88 <0.001
    Comorbidities 2.19 1.34–3.58 0.002
    Concomitant drugs 3.45 1.35–8.83 0.01
    Concomitant therapies 7.91 2.06–30.32 0.003
Effectiveness rate
    COPD exacerbation history 0.43 0.22–0.83 0.011
    Average daily dose 0.99 0.99–1.00 0.003
AEs: adverse events; OR: odds ratio; CI: confidence interval; COPD: 
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Figure 3. Effectiveness assessment at week 12 or 24 (effectiveness 
analysis set).
Table 5. FEV1 values before and after drug administration
Variable No. of patients FEV1, L Difference p-value
Before administration 476 1.46±0.47 - -
After 12 weeks of administration 149 1.46±0.56 0.05±0.23 0.007
After 24 weeks of administration 150 1.44±0.52 0.00±0.25 0.832
Values are presented as mean±SD. Difference indicates difference from baseline data.
FEV1: forced expiratory volume in 1 second; SD: standard deviation.
Table 6. Factors associated with incidence rate of effectiveness rate: univariate analysis
Variable Improvement No improvement p-value
History of exacerbation
    Yes 182 (91.00) 18 (9.00) 0.004
    No 562 (96.23) 22 (3.77)
Smoking history
    Ex-smoker 444 (95.69) 20 (4.31) 0.048
    Smoker 140 (90.91) 14 (9.09)
    Non-smoker 149 (96.13) 6 (3.87)
Average daily dose, μg
    150 679 (95.77) 30 (4.23) 0.003*
    ≥150 and <300† 11 (100) 0 (
    300 54 (84.38) 10 (15.63)
Values are presented as number (%).
p-value by chi-square test.
*By Fisher’s exact test. †Total daily dose was divided by treatment days (dose change during treatment period). 
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and ‘worsening’ cases. Most of the patients either showed an 
improvement in their COPD condition or the condition was 
maintained, while only 5.1% patients exhibited worsening of 
symptoms (Figure 3). 
Mean value of FEV1 collected from 476 patients before drug 
administration was 1.46±0.47 L and 149 patients (31.3%)  re-
peated pulmonary function test at week 12. The mean value 
of FEV1 was statistically increased by 0.05±0.23 L (p=0.007) 
(Table 5).
Within several factors considered for the effectiveness as-
sessments, the results showed that there was a statistically sig-
nificant relationship between the effectiveness rate and three 
key factors: COPD exacerbation history (p=0.004), smoking 
history (p=0.048), and average daily dose of the study drug 
(p=0.003) (Table 6). In multivariable analysis, COPD exacer-
bation history (p=0.011) and average daily dose of study drug 
(p=0.003) were independent factors that affect the effective-
ness rate (Table 4).
Discussion
This interim analysis of PMS study was conducted in order 
to demonstrate the safety and effectiveness of indacaterol (150 
μg and 300 μg) in COPD patients in South Korea. Both the 
doses (150 μg and 300 μg) were well tolerated with a lower 
incidence of AEs and causality related to the study drug. The 
overall condition of patients included in this study, based on 
physician assessment, was either improved or maintained; 
only few patients (5.1%) exhibited worsening of symptoms. 
AEs reported by patients were mostly mild or moderate. 
Moreover, the incidence rate of unexpected AEs reported was 
also less and could be resolved, reflecting a good safety profile 
of indacaterol in real-world setting. In most of clinical trials, 
it has been shown that indacaterol is generally safe and well 
tolerated in patients with moderate-to-severe COPD4. In a 
pooled analysis of data from all completed indacaterol clinical 
trials of at least 12-week duration in patients with moderate-
to-severe COPD, no significant safety issues were observed 
with indacaterol use9. Here, the most common events were 
COPD worsening, nasopharyngitis, headache, cough, and 
upper respiratory tract infection. In this analysis, the mean 
percentage of attended visits at which patients experienced 
cough after inhalation of indacaterol ranged from 14.1% to 
18.4% across the indacaterol dose groups (75, 150, 300, and 
600 μg) and for the majority of these patients, the cough start-
ed within 15 seconds of inhalation and lasted ≤15 seconds. 
Long-term studies, like the INDORSE study, have shown that 
the tolerability profile of indacaterol in patients with mod-
erate-to-severe COPD was similar to that reported in short-
term trials, with the majority of AEs being mild-to-moderate in 
severity10. The incidence of AEs and SAEs were 76%, 77% and 
10.4%, 12.3% in indacaterol treatment groups with 150 μg and 
300 μg, respectively. However, the incidence rate of AEs in our 
study was 22.4%, much lower than previous study. We assume 
there is likelihood that AEs were less frequently reported in a 
real-world clinical setting of South Korea with short study pe-
riod compared to phase III clinical trials. Also, the incidence of 
AEs with indacaterol therapy in Asian patients with moderate-
to-severe COPD was found to be similar as in the Caucasian 
population7. Recently, a post-marketing study conducted in 
Japan to evaluate the efficacy of indacaterol, 150 μg on QoL 
(modified Medical Research Council, dyspnoea scale and 
COPD Assessment Test) and pulmonary function, showed 
that indacaterol was effective and well tolerated as a broncho-
dilator for management of patients with COPD11. Real-world 
studies provide a better picture of effectiveness and safety of 
an approved drug in clinical-practice across diverse popula-
tion. In one such study (INFLOW) where various bronchodi-
lators including indacaterol were evaluated in COPD patients 
across Middle East, Asia and South Africa, an improvement in 
health status was reported and the bronchodilators were well-
regarded by both the physicians as well as patients12. Since 
this is an observational study in which there are no placebo or 
comparators, one must be careful in predicting the actual fac-
tors which may influence the AEs and the effectiveness of the 
study drug. In this real-world study, inherent reporting bias, 
stability of concomitant medications, and physician’s subjec-
tive evaluation at different centers could be limiting factors. 
However, low number of reported AE and SAEs along with 
proven effectiveness of indacaterol in this study re-establishes 
the outcomes of clinical trials, indicating indacaterol as an ef-
fective and well-tolerated bronchodilator option for the main-
tenance treatment of COPD patients. 
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